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Background: There remains a critical need for more effective, safe, long-term treatments for cystic fibrosis (CF). Any
successful therapeutic strategy designed to combat the respiratory pathology of this condition must address the
altered lung physiology and recurrent, complex, polymicrobial infections and biofilms that affect the CF pulmonary
tract. Cysteamine is a potential solution to these unmet medical needs and is described here for the first time as
(Lynovex®) a single therapy with the potential to deliver mucoactive, antibiofilm and antibacterial properties; both
in oral and inhaled delivery modes. Cysteamine is already established in clinical practice for an unrelated orphan
condition, cystinosis, and is therefore being repurposed (in oral form) for cystic fibrosis from a platform of over
twenty years of safety data and clinical experience.
Methods: The antibacterial and antibiofilm attributes of cysteamine were determined against type strain and
clinical isolates of CF relevant pathogens using CLSI standard and adapted microbiological methods and a BioFlux
microfluidic system. Assays were performed in standard nutrient media conditions, minimal media, to mimic the
low metabolic activity of microbes/persister cells in the CF respiratory tract and in artificial sputum medium. In vivo
antibacterial activity was determined in acute murine lung infection/cysteamine nebulisation models. The mucolytic
potential of cysteamine was assessed against DNA and mucin in vitro by semi-quantitative macro-rheology. In all
cases, the ‘gold standard’ therapeutic agents were employed as control/comparator compounds against which the
efficacy of cysteamine was compared.
Results: Cysteamine demonstrated at least comparable mucolytic activity to currently available mucoactive agents.
Cysteamine was rapidly bactericidal against both metabolically active and persister cells of Pseudomonas aeruginosa
and also emerging CF pathogens; its activity was not sensitive to high ionic concentrations characteristic of the CF
lung. Cysteamine prevented the formation of, and disrupted established P. aeruginosa biofilms. Cysteamine was
synergistic with conventional CF antibiotics; reversing antibiotic resistance/insensitivity in CF bacterial pathogens.
Conclusions: The novel mucolytic-antimicrobial activity of cysteamine (Lynovex®) provides potential for a much
needed new therapeutic strategy in cystic fibrosis. The data we present here provides a platform for cysteamine’s
continued investigation as a novel treatment for this poorly served orphan disease.
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Antibiotics, whether administered systemically or by in-
halation, remain a mainstay of the cystic fibrosis therapy
regimen [1]. Control and at least a degree of resolution
of the respiratory infections and bacterial colonisation
associated with cystic fibrosis is an essential component
of disease management. The altered physiology of the
cystic fibrosis respiratory tract makes this almost impos-
sible to achieve. The dehydrated mucus and sputum
create an ideal environment for microbial infection and
colonisation and a largely impenetrable barrier for ac-
cess of antibiotics to the bacterial pathogens they are
targeting [2].
The co-administration of mucolytic or osmotic agents
(e.g. DNAase/pulmozyme®, N-acetylcysteine/Mucomyst®
and mannitol/Bronchitol® [3]) to reduce mucus viscosity
and elasticity [4] is intended to facilitate increased antibiotic-
microbe contact. These therapies can also improve the pa-
tient’s ability to expectorate. There is insufficient evidence,
however, that these adjunct treatments affect overall anti-
biotic usage [5]. The antibiotic resistance which this sus-
tained antibiotic regimen inevitably leads to continues to
pose an ever-increasing clinical problem in the treatment
of cystic fibrosis [6,7]. The need to develop more effective
strategies for the resolution of mucus build up and the
eradication of the respiratory pathogens that infect and
colonise the respiratory tract in cystic fibrosis is acute.
The biofilm mode of growth of P. aeruginosa and other
bacterial pathogens in the cystic fibrosis lung also leads to
higher antibiotic tolerance. This is a further, compounding
factor in antimicrobial resistance development in cystic
fibrosis and the resulting reduction in effectiveness/
life-span of antibiotic treatments [8]. Unresolved infection
and acute exacerbations lead to a more rapid deterioration
in lung function and increased morbidity and mortality
[9]. This cycle can only really be broken by tackling, in
parallel, the mucus barrier and eradicating the bacteria it
hosts/protects, in both planktonic and biofilm form.
We initially investigated cysteamine as a biofilm and
mucus penetration enhancer for improved antibiotic deliv-
ery in cystic fibrosis [10,11]. This was on the basis of cys-
teamine’s previously described ability to selectively disrupt
disulphide bonds [12]. Cysteamine was indeed an effective
mucolytic and biofilm disrupter/preventer, outperforming
currently licensed mucolytic/osmotic agents in these
functions. Surprisingly, cysteamine was also directly anti-
microbial against P. aeruginosa; including mucoid and non-
mucoid strains and clinical isolates. Cysteamine was also
active against other cystic fibrosis bacterial pathogens.
Cysteamine dramatically increased the antimicrobial activ-
ity of tobramcyin, ciprofloxacin and colistin; synergising
to enhance their potency, increase their spectrum of activ-
ity against broader panels of cystic fibrosis relevant bac-
teria and delivering a marked post-antimicrobial effect.The intention is to develop cysteamine/Lynovex® for
application alongside existing antibiotic therapies. As an
adjunct treatment, this may extend the utility and lifespan
of conventional antibiotics, whilst at the same time poten-
tially reducing dosing levels and frequency. Of major
significance, cysteamine/Lynovex® could help ameliorate
or even prevent antimicrobial resistance development
if the data we have obtained thus far translates in clin-
ical practice.
Cysteamine is already approved in other non-related
clinical indications such as cystinosis and as such, has an
established safety profile and has been in clinical use since
1994 [13]. Our own work goes further to demonstrate at
least preliminary in vivo tolerability and safety following
respiratory tract delivery (nebulisation or intratracheal
administration) of cysteamine in murine lung infection
models. These in vivo studies (acute P.aeruginosa lung
infection models) provided further compelling initial
evidence of the antimicrobial activity of cysteamine even
when used as a monotherapy in nebulised form against
mucoid isolates of P. aeruginosa.
The novel properties we describe here for cysteamine
are potentially directly applicable to cystic fibrosis and
may provide a much needed solution to the urgent need
for new therapeutic strategies for this still poorly served,
life limiting condition.
Methods
Bacterial strains and culture conditions
Bacteria included in this study are listed in Additional
file 1: Table S1 and summarised in Table 1. Strains were
grown in Mueller-Hinton (MH) broth or agar plates at
37°C. All chemicals and reagents were obtained from
Sigma-Aldrich (UK), unless otherwise stated. NH57388A
is a mucoid strain of P. aeruginosa and NH57388B is a
non-mucoid strain of P. aeruginosa [14].
Antibiofilm activity
The effect of cysteamine and other mucolytic and anti-
biotic agents on biofilm prevention of P. aeruginosa PAO1
were visualized using a Bioflux microfluidic system (Fluxion,
USA) and transmitted light microscopy (Axiovert 40,
Carl Zeiss, UK). Compounds tested included cysteamine
and other mucolytic agents (N-acetylcysteine, DNase I,
alginate lyase) and tobramycin.
Outlet wells of 48-well microfluidic flow cell plates
(Fluxion, USA) were primed with 0.5 × MH broth for
1 min and then inoculated with 200 μl of a mid-late expo-
nential phase culture of P. aeruginosa PAO1 (OD625 ~ 0.7)
in MH broth for 5 s at 1 Dyn/cm2 via the outlet wells. The
flow cell plates were then incubated statically at 37°C for
45 min to allow the bacteria to adhere to the glass flow
cells. Images were captured from all experimental capillar-
ies (× 40 magnification) at this time point (t = 0 h). The
Table 1 Minimum inhibitory concentrations and MIC
ranges of cystic fibrosis respiratory pathogens versus
cysteamine
Bacteria (n = 103) Median MIC100 (μg/ml) Range (μg/ml)
P. aeruginosa (n = 42) 250 250-500
P. fluorescens (n = 2) 250-500 250-500
P. putida (n = 1) 250 NA
B. cepacia (n = 3) 250 250-500
B. cenocepacia (n = 3) 500 500-1000
B. multivorans (n = 3) 500 500
Ach. xylosidans (n = 7) 500 250-500
Ach. denitrificans (n = 1) 500 NA
Al. faecalis (n = 2) 250-500 250-500
C. indologenes (n = 2) 250-500
K. pneumoniae (n = 3) 250 250-1000
Pan. apista (n = 1) 500 NA
Pan. pnomenusa (n = 1) 1000 NA
R. pickettii (n = 3) 500 500-1000
R. mannitolilytica (n = 1) 500 NA
Sph. paucimobilis (n = 2) 1000 1000
St. maltophilia (n = 7) 500 250-1000
S. aureus (n = 14) 250 250-500
Data are median MIC100 of triplicate samples in experiments repeated 3 times.
P = Pseudomonas, B = Burkholderia, Ach = Achromobacter, Al = Alcaligenes,
C = Chryseomonas, K = Klebsiella, Pan = Pandoraea, R = Ralstonia,
Sph = Sphingomonas, St = Stenotrophomonas, S = Staphylococcus, NA = Not
applicable.
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troduced into the inlet well. Flow was established at 0.5
Dyn/cm2 at incubation at 37°C for 16 h was initiated. Two
specific adjacent capillaries were selected and photo-
graphed every 15 min for the 16 h incubation to create an
.avi movie. At t = 16 h, all capillaries were again photo-
graphed at × 40 magnification. All images were captured
using a QImaging QICAM camera and analysed using
QCapture Suite software (QImaging, Canada). All experi-
ments were carried out at least 3 times, and presented im-
ages and movies are representative of a single experiment.
To determine whether cysteamine, tobramycin or
combinations thereof elicited a post-antimicrobial effect,
at the conclusion of biofilm prevention experiments,
10 μl samples of cells were removed from each outlet
well and added to 190 μl MH broth and incubated in a
96-well microplate for 24 h at 37°C, with no added anti-
microbials, and recovery of growth was monitored by
taking hourly absorbance readings (625 nm) using a Bio-
Tek Synergy microplate reader (BioTek, USA).
The minimum bacterial eradication concentration
(MBEC) was determined against biofilms of P. aerugi-
nosa ATCC27853 and P. aeruginosa DSMZ1299 using
the method of O’Neill, et al. [15] with the followingmodifications. Isolates were cultured for 24 h at 37°C in
5 ml of MH broth. Cultures were diluted to the 0.5
McFarland Standard in MH broth and 200 μl aliquots
were added to each well of a 96-well tissue culture-
treated polystyrene plate. After 24 h growth at 37°C, the
plates were washed three times with phosphate-buffered
saline (PBS) to remove any unattached bacteria and
treated with test compound for 24 h. Following this sec-
ond incubation plates were washed three times with PBS
to remove any unattached bacteria then dried for 1 h at
60°C prior to staining with 0.4% crystal violet solution.
The optical density (492 nm) was used as an index of
bacterial adherence to the surface and biofilm formation.
Experiments were performed in triplicate, the results
were averaged, and standard errors were calculated. To
compensate for background absorbance, OD readings of
the sterile medium with both the fixative and dye were
averaged and subtracted from all of the experimental
values. A biofilm-positive phenotype was defined as
OD ≥ 0.2 at 492 nm.
Mucolytic activity
The macrorheological impact of cysteamine on individ-
ual mucus components was determined by quantifying
changes in viscoelasticity of a sterile 20% (w/v) solution
of porcine mucin solution or a sterile 5 mg/ml calf thy-
mus DNA solution following exposure to cysteamine
versus other, control mucolytic agents [16]. Mucolytic
treatments were prepared at 10 mg/ml and exposed to
20% (w/v) mucin solution for 16 h at 37°C. For DNA,
cysteamine was tested at concentrations of 1 mg/ml and
125 μg/ml and recombinant human DNAse I (rhDNase
I) was tested at 10U/ml. In both experiments, an equiva-
lent volume of water (4 μl) was used as a control for
possible dilution effects. Changes in mucin and DNA
viscoelasticity were determined by distance travelled
(mm) as a function of time (min) through sterile 1 ml
serological pipettes (Greiner Bio-One; 2.77 mm internal
bore) at room temperature.
Effect of cysteamine on mucin production by normal
human bronchial epithelial (NHBE) cells
NHBE cells (Lonza Group Ltd, UK) were cultured
according to the suppliers’ instructions. Cells were trans-
ferred from their growth media to Clonetics B-ALI air-
liquid interface medium (Lonza Group Ltd, UK) (basal
aspect only) and to collagen-coated 24-well transwells at
a density of 5 × 104 cells per insert. Fully differentiated
monolayer cultures were generated per supplier’s in-
structions. Transwells were then treated with 1 mg/ml
cysteamine (added to the basal layer medium) or with B-
ALI media only (untreated controls) for 7 d, with media/
treatment changed in all cultures every 48 h. Free apical
fluid generated by each of the monolayers was collected
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ation were then assessed in all cultures by a method based
on that of Handra-Luca and co-workers [17]; transwell fil-
ters and cells were fixed with 10% (v/v) formalin, pH 7.0
for 24 h, rinsed with sterile PBS and stained with Alcian
blue (1% in 3% (v/v) acetic acid, pH 2.5 for 15 min, photo-
graphed for assessment of gross staining levels and mono-
layers examined microscopically.
Antibacterial susceptibility testing
Minimum Inhibitory Concentrations (MICs) were de-
termined by the broth microdilution procedure de-
scribed in Clinical and Laboratory Standards Institute
(CLSI) approved standard M07-A9 [18]. Additionally,
MICs were determined as described above, but in arti-
ficial sputum medium [19] and M9 minimal medium
[20]. The MIC100 of cysteamine and other test item an-
timicrobials employed in this study was determined as
the lowest concentration of antimicrobial showing total
inhibition of bacterial growth.
Determination of the effect of combinations of
cysteamine and antibiotics versus P. aeruginosa PAO1
To determine whether the interaction of cysteamine with
the antibiotics tobramycin, colistin, ciprofloxacin and gen-
tamicin was synergistic, additive, antagonistic or there was
no effect the Fractional Inhibitory Concentration (FIC)
was determined after carrying out checkerboard MIC test-
ing [21]. For all of the wells of the microdilution plates
that corresponded to an MIC, the sum of the FICs (ΣFIC)
was calculated for each well with the equation ∑FIC =
FICA + FICB = (CA/MICA) + (CB/MICB), where MICA
and MICB are the MICs of drugs A and B alone, respect-
ively, and CA and CB are the concentrations of the drugs
in combination, respectively.
In vivo efficacy & tolerability
Cysteamine was administered directly into the lungs of
mice (post-infection with P. aeruginosa) either by intratra-
cheal delivery or nebulisation in murine models of respira-
tory infection by Ricerca Biosciences LLC (Taiwan) and
Euprotec Ltd (UK), respectively.
Briefly, in the first study (Ricerca), groups of 5 ICR male
mice were immunosuppressed prior to intranasal infection
(3–10 × 104 CFU/mouse P. aeruginosa ATCC27853). Cys-
teamine (5 mg/kg) or tobramycin (3 mg/kg) were then ad-
ministered intratracheally (IT) in 2 doses, 10 min and 6 h
following infection In the second study (Euprotec), groups
of 8 immunosuppressed ICR mice were infected with P.
aeruginosa EUPPA103 (6.5 × 104 CFU/mouse by intrana-
sal injection). Mice were nebulised 1 h post-infection with
aqueous cysteamine (one dose of 4.2 mg/ml for 5, 10 or
20 min) or aqueous tobramycin (4.2 mg/ml for 10 min).Endpoints of both studies were assessment of lung tissue
bacterial burden 25 h post-infection. Statistical analyses
were performed for the second study using StatsDirect -
Kruskal-Wallis: all pairwise comparisons (Conover-Inman)
for vehicle versus treatment group comparison. The lower
limit of detection was approximately 50 CFU/g of lung
tissue.
Results and discussion
Antibiofilm activity of cysteamine
The ability of cysteamine and cysteamine hydrochloride
to prevent formation of P. aeruginosa PAO1 biofilms was
compared with other mucoactive compounds currently
used in clinical practice, or in development as a treatment
for CF (rhDNAse I, alginate lyase and N-acetylecysteine)
was determined using the Bioflux 200 microfluidic system.
Cysteamine and cysteamine hydrochloride were effective
in preventing P. aeruginosa biofilm formation (Figure 1A-b,
1A-d), as no microbial growth is seen, and superior to the
other mucolytic agents tested; N-acetylcysteine (Figure 1A-c),
rhDNase I (Figure 1A-e) and alginate lyase (Figure 1A-f),
where biofilm formation is clearly evident, as also seen
in the untreated control (Figure 1A-a).
The biofilm prevention potential of cysteamine was then
investigated in the presence of one of the cystic fibrosis
‘gold standard’ antibiotics, tobramycin. A synergistic trend
was observed (Figure 1B-e) in that tobramycin potentiated
the antibiofilm activity of cysteamine and vice versa
whereas alone, neither cysteamine (Figure 1B-c) nor
tobramycin (F1B-d) prevented significant biofilm forma-
tion. This is especially interesting as the concentration
of cysteamine used was subsequently determined to be
2.5-times lower than the MIC100 of cysteamine versus P.
aeruginosa PAO1, although the MIC100 of this strain to
tobramycin was 1 μg/ml. It should be pointed out that
the biofilm inoculum was a much more cell-dense, ex-
ponential growth phase culture of P. aeruginosa PAO1
(OD625 ~ 0.7), not the usually applied CLSI inoculum
of ~5 × 105 cfu/ml (OD625 < 0.1) [18], so both putative
antibiofilm agents were being tested at levels signifi-
cantly below their MIC100 value. Therefore, a sub-MIC
concentration of cysteamine acted synergistically with
tobramycin to prevent biofilm formation. This was our
first evidence of cysteamine having a direct antimicrobial
effect against P. aeruginosa versus it being solely antibio-
film in function. Moreover, when comparing Figure 1A-c
(N-acetylcysteine) and 1A-e (rhDNase I) to Figure 1B-e,
the combination of cysteamine and tobramycin was more
potent in biofilm prevention than existing clinical muco-
active used for CF treatment.
Prevention of P. aeruginosa and other bacterial biofilms
is a highly desirable characteristic for any new CF candidate
therapy, but in the clinical setting, a truly effective CF treat-














Figure 1 Antibiofilm activity against P. aeruginosa PAO1 Biofilms
of A – cysteamine, N-Acetylcysteine, rhDNase and alginate lyase
and B – cysteamine and cysteamine in combination with
tobramycin. A- a: Untreated control; b: 1 mg/ml Cysteamine;
c: 1 mg/ml N-acetylcysteine; d: 1 mg/ml Cysteamine hydrochloride;
e: 1 mg/ml rhDNase I; f: 1 mg/ml Alginate lyase. B- a: Control 0 h;
b: Control 16 h; c: 100 μg/ml cysteamine; d: 10 μg/ml tobramycin;
e: 100 μg/ml cysteamine & 10 μg/ml tobramycin. In all cases,
P. aeruginosa PAO1 biofilms were seeded, and their growth
monitored, in the presence of the mucoactive and/or antibacterial
compounds listed above for 16 h in the BioFlux200 microfluidic system
at a flow rate of 0.5 Dyn/cm2.
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able to disrupt and even eradicate bacteria growing in
established biofilms. As such, the biofilm eradication
potential of cysteamine was assessed by determining its
Minimum Biofilm Eradication Concentration (MBEC)against two P. aeruginosa biofilms (2a – DSMZ1299 &
2b – ATCC27853). As shown in Figure 2A-B, cysteamine
was able to eradicate P. aeruginosa biofilms with an
MBEC of 625 μg/ml (~2-3 times the MIC100; Table 1).
Mucolytic activity of Cysteamine versus Mucin and DNA
Cysteamine has already been described as disulfide bond
disrupter [12]. This, plus its ability to disrupt biofilms
and prevent their formation, as described above, led us to
investigate cysteamine’s potential as a mucolytic/mucus
penetration-enhancing agent. Specifically, the impact of
cysteamine on the macrorheology (viscosity and elasticity)
of mucin and DNA [22-24] was assessed. Mucin and
DNA are important macromolecular components of cystic
fibrosis sputum [24]. The effect of cysteamine on mucin
and DNA viscoelasticity was assessed and compared to
mucoactive agents already used in cystic fibrosis therapy
(N-Acetylcysteine and rhDNAse I) or under investigation
as potential therapeutic agents for cystic fibrosis (alginate
lysae) [22,23]. The increased velocity (reduced viscosity
and elasticity) observed for mucin (Figure 3) following a
single exposure to cysteamine (8.8 mm/sec ±0.5) or cyste-
amine hydrochloride (8.4 mm/sec ±0.5) versus untreated
mucin (<1 mm/sec) indicates significant mucoactive po-
tential. Moreover, the impact of cysteamine/cysteamine
hydrochloride on mucin macrorheology was greater than
that observed for N-acetylcysteine (N-acetylcysteine treated
mucin having a velocity of 4.4 mm/sec ±1.0), DNase I and
alginate lyase (neither of these mucoactive agents having
any impact on mucin velocity/rheology properties). The ef-
fect of cysteamine on changes in DNA viscosity (Figure 4)
was less pronounced than with mucin and effectively neu-
tral. Unsurprisingly, cysteamine was inferior to rhDNase I.
Effect of cysteamine on mucin production by normal
human bronchial epithelial (NHBE) cells
Although the isolated porcine mucin and DNA rheology
assays are very good indicators of cysteamine’s mucoac-
tive potential, we went further to assess its properties
against mucin as a component of respiratory epithelial
cell-derived mucus; in a more complex and physiological
relevant human system employing differentiated NHBE
cells. Figure 5(A) demonstrates the presence of mucin
within NHBE monolayer cultures as a function of the in-
tensity of Alcian blue staining and that it is significantly
reduced (less blue, only background staining versus spe-
cific matter) on monolayers exposed for 7 d to cysteamine
versus those exposed to control media only. Figure 5(B)
demonstrates the presence at a microscopic level of more
Alcian blue-stained material within the cultures in control
non-cysteamine treated cells versus cysteamine-treated
cells. Finally, Figure 5(C) demonstrates that the disrup-
tion/reduction of mucin in the cysteamine treated cultures
as indicated by less Alcian Blue staining also results in a
A B
Figure 2 Determination of the minimum biofilm eradication concentration of cysteamine against established P. aeruginosa DSMZ1299
(A) and P. aeruginosa ATCC27853 (B) biofilms. Cys – cysteamine. The optical density (492 nm) of crystal violet released from adherent cells
within 24 h biofilms was used as an index of biofilm formation. A biofilm-positive phenotype was defined as OD ≥ 0.2. To compensate for
background absorbance, OD readings of the sterile medium with both the fixative and dye were subtracted from all the experimental values.
Experiments were performed in triplicate and results are presented as means. Error bars represent the standard error of the mean.
Charrier et al. Orphanet Journal of Rare Diseases 2014, 9:189 Page 6 of 11
http://www.ojrd.com/content/9/1/189greater volume of free apical surface liquid/fluid. This is
to be expected if less intact mucin molecules are present
to bind water and other airway surface fluid components
in the apical mucus layer. The NHBE cell assay confirms
the mucoactive properties of cysteamine in a physiologic-
ally relevant primary lung epithelial monolayer based sys-
tem and also demonstrated that even relatively high levels
of cysteamine were non-toxic to the NHBE cells.Figure 3 Positive macro-rheologic impact of cysteamine,
N-Acetylcysteine, rhDNase and alginate lyase on mucin. 20%
(w/v) porcine stomach mucin was exposed to the 10 mg/ml of the
cysteamine and the mucoactive agents listed above for 24 h at 37°C
and the viscosity of the samples determined by measuring velocity
(distance moved (mm) over time (s)). An equal volume of distilled
water (4 μl) was used as a control. The experiment was carried out
in triplicate and the bars represent the mean.Antimicrobial activity of Cysteamine
Following the identification of antibiofilm properties that
also pointed to a direct antimicrobial activity of cysteamine
against P. aeruginosa PAO1, ATCC27853 and DSMZ1299,
the antibacterial potential of cysteamine was assessed
against a panel of CF bacterial pathogens. Table 1 shows
a summary of the direct antimicrobial activity (median
MIC100 and range (μg/ml)) of cysteamine against a range
of Gram negative and Gram positive bacteria characteristicFigure 4 Neutral macro-rheologic impact of cysteamine and
rhDNase on DNA. 5 mg/ml calf thymus DNA was exposed to
1 mg/ml or 125 μg/ml of cysteamine and 10 U/ml rhDNase I for 2 h
at 37°C and the viscosity of the samples determined by measuring
velocity (distance moved (mm) over time (s)) DNase – rhDNAse I;
Cys – cysteamine. The experiment was carried out in triplicate and








Figure 5 Cysteamine disrupts production of normal human bronchial epithelial (NHBE) cell-derived mucus. Differentiated NHBE
monolayers were exposed (basally) to 1 mg/ml cysteamine or control culture media for 7 days. Mucin production at the apical aspect was then
assessed by Alcian blue staining macro- and microscopically (panels A & B) and the amount of free, non-mucin bound airway surface fluid
quantified (panel C).
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mucoid and non-mucoid P. aeruginosa. Mucoid strains
are alginate producers and are therefore generally less sus-
ceptible to conventional antibiotics and (non-alginate lyase)
mucoactive agents. A complete list of individual MICs for
all strains tested can be found in Additional file 1: Table S1.
Cysteamine showed direct antimicrobial activity (MIC100)
at concentrations in the range of 250–500 μg/ml against P.
aeruginosa and other CF pathogens including BurkholderiaCysteamine MIC100 (µg/ml)
Strain High metabolic activity Low metaboli
P. aeruginosa PAO1 250 62.5
P. aeruginosa NH57388A 250 31.25
P. aeruginosa NH57388B 125 15.6
A B
Figure 6 Antibacterial efficacy of cysteamine and tobramycin on P. ae
conditions. The MIC100 of P. aeruginosa PAO1, P. aeruginosa NH57388A an
CLSI conditions for – A) nutrient replete media (MH broth), whereas –
nutrient-limiting conditions. The graphs (A & B) show data for P. aerug
from triplicate experiments. Error bars represent the Standard Error of the Mea
a non-mucoid strain. * - P. aeruginosa NH57388B is tobramycin resistant.cepacia complex, Staphylococcus aureus and also emerging
pathogens including Achromobacter xylosidans, Stenotro-
phomonas spp and Ralsatonia spp (data not shown).
Bacteria in the CF lung grow in biofilms under nutrient-
limited conditions [25], so the antibacterial efficacy of
cysteamine was assessed under nutrient limiting (M9 min-
imal medium) and excess nutrient (MH broth) conditions.
Under the more physiologically relevant, nutrient-limiting
assay conditions (Figure 6), the MIC100 of cysteamineTobramycin MIC100 (µg/ml)




ruginosa incubated under nutrient-limiting and Nutrient replete
d P. aeruginosa NH57388B were determined according to standard
B) M9 minimal medium was substituted for MH broth to provide
inosa PAO1. The table shows the mean MIC of triplicate samples
n. P. aeruginosa NH57388A is a mucoid strain. P. aeruginosa NH57388B is
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the MIC100 of tobramycin was unchanged, suggesting a
cysteamine mechanism of action that is not dependent
on metabolic activity. This data suggests that not only is
cysteamine a biofilm prevention and disrupting agent
(Figures 1 and 2), but is also directly antibacterial against
CF pathogens (Table 1) and importantly, demonstrates
improved efficacy under nutrient limited conditions such
as within the CF lung environment.
Antimicrobial activity of cysteamine in combination with
conventional cystic fibrosis antibiotics
As an antibiofilm/mucolytic agent, cysteamine would
almost certainly be used in a clinical setting alongside
currently available antibiotics as a means to facilitate
their access to target pathogens. A synergistic relation-
ship between tobramycin and cysteamine was observed
in our biofilm assays (as described above; Figures 1 & 2),
so we next investigated the antibacterial potential of cyste-
amine in combination with CF antibiotics (Table 2). In-
deed, at least additive or synergistic activity was observed
in combination with tobramycin, ciprofloxacin, colistin
and gentamicin against five strains of P. aeruginosa
(PAO1, PA14, Pa058, NH57388D and NH57388A). Most
significantly, the MIC100 of colistin, tobramycin and genta-
micin were reduced up to 16-fold when combined with
cysteamine. In certain cases, antibiotic resistance was re-
versed. For example, P. aeruginosa Pa058 is a ciprofloxa-
cin resistant clinical isolate (MIC100 = 32 μg/ml), based on
CLSI breakpoints [26] and has a cysteamine MIC100 of
500 μg/ml. However, when used in combination an addi-
tive FIC was obtained and the MICs of cysteamine and
ciprofloxacin were 250 μg/ml and 1 μg/ml, respectively.
This means that in the presence of cysteamine, P. aerugi-
nosa Pa058 becomes sensitive to ciprofloxacin, i.e. reversal
of resistance. In another instance, the tobramycin resistant
strain, P. aeruginosa NH57388D (MIC100 = 16 μg/ml)
had its resistance reversed in the presence of cysteamine
(2 μg/ml). Because aminoglycosides are associated with
a degree of nephrotoxicity and ototoxicity [27], their use
in combination with cysteamine may provide a meansTable 2 Analysis of the Fractional Inhibitory Concentration In
Antibiotics versus P. aeruginosa
Tobramycin Ciprofloxacin
Strain Syn Add Ind Syn Add In
PAO1 6 5 0 0 3 5
Pa14 0 7 0 0 2 5
Pa058 0 8 0 0 11 1
57388A 2 5 0 0 2 1
57388D 4 4 0 0 4 1
Numbers in the table indicate the number of replicates demonstrating these effects
for any of the cysteamine-antibiotic combinations. P. aeruginosa Pa14 is colistin res
colistin and tobramycin resistant and P. aeruginosa 57388A is ciprofloxacin and tobto lower the antibiotic concentration required while
retaining or even enhancing their antimicrobial effect
whilst reducing toxicity. Furthermore, the combined use
of antimicrobials with different mechanisms of action is
believed to aid in the ever-increasing incidence of anti-
biotic resistance [28].
The activity of cysteamine in combination with tobra-
mycin was next determined under more physiologically
relevant conditions that better resemble cystic fibrosis
sputum; the biological matrix in which cysteamine will
need to function if it is to be effective in vivo [19]. The MIC
of cysteamine against 4 P. aeruginosa (PAO1, ATCC27853,
DSMZ1128 and DSMZ1299) in artificial sputum medium
(Table 3) ranged between 250 and 500 μg/ml, as it did
under standard CLSI conditions (MH broth). In addition
to there being no significant inhibition of cysteamine anti-
microbial activity under artificial sputum conditions, the
same degree of synergy between tobramycin and cyste-
amine was observed as per standard CLSI broth microdi-
lution conditions (Table 3), the FIC index for the 4 P.
aeruginosa strains was between 0.5 and 1 in both con-
ditions. Of note, the CLSI interpretive standard for
tobramycin sensitivity against P. aeruginosa is ≤4 μg/ml,
emphasising the dramatic reduction in MIC in the pres-
ence of cysteamine in all conditions in which we tested its
activity.
Following biofilm prevention experiments, samples were
analysed to determine whether cysteamine elicited a post-
antimicrobial effect (PAE) on bacteria. Kinetic growth
assays on these samples did reveal a post-antimicrobial
effect; namely in that delayed growth of bacteria from
cysteamine-treated (non-biofilm forming) cells was ob-
served, but interestingly, no delayed growth/PAE was ob-
served in samples from tobramycin-treated cells/biofilms
(Figure 7A). Combinations of tobramycin and cysteamine
however exerted a greater PAE than cysteamine adminis-
tered as a mono-treatment (Figure 7B). It is likely that the
PAE seen after treatment with combinations of these anti-
microbial agents is a result of continued/sustained interac-
tions with their bacterial targets. For example, the PAE
of rifampicin, which targets bacterial RNA polymerase,dex (FICI) of Cysteamine with Cystic Fibrosis-relevant
Colistin Gentamicin
d Syn Add Ind Syn Add Ind
3 4 4 1 5 0
5 7 0 0 5 0
0 6 4 0 6 0
2 6 0 1 6 0
2 7 0 1 5 0
. Syn = synergy, Add = Additive, Ind = Indifferent. No antagonism was observed
istant, P. aeruginosa Pa058 is ciprofloxacin resistant, P. aeruginosa 57388A is
ramycin resistant. P. aeruginosa PAO1 is sensitive to all antibiotics tested.
Table 3 Comparison of the Antibacterial Activity of Cysteamine and Tobramycin in Artificial Sputum Medium and
under standard CLSI conditions
Mueller Hinton Broth MIC100 (μg/ml) Artificial Sputum Medium MIC100 (μg/ml)
Isolate Cysteamine Tobramycin Cysteamine Tobramycin
P. aeruginosa PAO1 250 1 500 4
P. aeruginosa DSMZ1128 250 1 250 2
P. aeruginosa DSMZ1299 250 1 250 1
P. aeruginosa ATCC27853 250 1 500 2
Data represents the mean MIC100 (μg/ml) of triplicate samples from triplicate experiments. MICs were determined using the broth microdilution procedure from
CLSI Approved Standard M07-A9 [18], with artificial sputum medium substituted for MH broth as appropriate. Data represents the mean MIC100 (μg/ml) of
triplicate samples from triplicate experiments.
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protein synthesis [29]. The PAE observed for cysteamine
potentially has significant implications for clinical dosing
regimens; a combination of cysteamine and tobramycin
may have the potential for longer dosing intervals and
lower doses therein than treatment with tobramycin alone.
In vivo efficacy & tolerability
To assess whether the in vitro antibiofilm and antibacter-
ial data derived in our studies translated in a more clinic-
ally relevant, complex biological setting, we employed a
well-established mouse model of P. aeruginosa lung in-
fection and determined the impact therein of cyste-
amine exposure on lung bacterial burdens. We also
assessed how well tolerated cysteamine was when deliv-
ered via the respiratory route as to date, its safety and
toxicological potential have not been determined by thisA
B
Figure 7 Post-Antimicrobial effect (PAE) of cysteamine, tobramycin an
(A) and combinations thereof (B) on the recovery of growth of P. aerugino
antimicrobial agents for 16 h was monitored for 24 h post termination of c
HT microplate reader.mode of application. Cysteamine was well tolerated and
did not cause any adverse effects when administered to
mice via two respiratory routes; either by a single dose
of cysteamine or tobramycin delivered by nebulisation
(4.2 mg/ml for 5 min, 10 min or 20 min) following in-
fection with P. aeruginosa EUPPA103 (Figure 8A), or
two doses (5 mg/kg each) delivered intratracheally 10 min
and 6 h after infection with P. aeruginosa ATCC27853
(Figure 8B). These experiments provide the first evidence
of in vivo antibacterial efficacy of cysteamine in respiratory
tissue. In the mice infected with P. aeruginosa EUPPA103,
nebulised cysteamine (4.2 mg/ml, 5 – 20 min exposure)
significantly reduced bacterial lung burden (LogR 0.94-
1.11 cfu/g; P ≤ 0.001) compared to vehicle only treated
mice (StatsDirect Kruskal-Wallis test: Squared ranks ap-
proximate equality of variance test). Tobramycin (4.2 mg/ml
aqueous solution) treated mice also demonstrated statisticallyd combinations thereof. The impact of cysteamine or tobramycin
sa PAO1 cells that had been exposed to either/both of these
ysteamine or/and tobramycin treatment at 37°C in a BioTek Synergy
AB
Figure 8 Antimicrobial activity of cysteamine following
nebulisation (A) and intra-tracheal dosing (B) in a mouse acute
lung infection model. (A) The clinical strain P. aeruginosa
EUPPA103 was administered at ~6.5 × 104 CFU/mouse by intranasal
injection under temporary inhaled anesthesia. Mice were placed
within sealed nebulisation chamber and exposed to cysteamine at
4.2 mg/ml for 5, 10 or 20 minutes (total 1 dose) or tobramycin at
4.2 mg/ml in aqueous solution for 10 minutes via aerosol delivery
system 1 hour post-infection. Experimental endpoint was lung tissue
burden 25 h post-infection. Vehicle was sterile physiological water.
The lower limit of detection was approximately 50 cfu/g of tissue.
(B) The clinical strain P. aeruginosa ATCC27853 was administered at
3 × 104 - 1 × 105 cfu/40 μl/mouse by intranasal injection under temporary
inhaled anesthesia. Mice were given two doses (5 mg/kg each) of
cysteamine or tobramycin delivered intratracheally 10 min and 6 h
after infection. Experimental endpoint was lung tissue burden 26 h
post-infection. Vehicle was sterile physiological water. The lower
limit of detection was approximately 50 cfu/g of tissue.
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http://www.ojrd.com/content/9/1/189significant reduction in lung burden (LogR 1.51 CFU/g;
P = 0.0 117) (StatsDirect Kruskal-Wallis test: all pairwise
comparisons (Conover-Inman)). A trend to dose depend-
ency for cysteamine was observed, with greatest efficacy
demonstrated by 20 min exposure (5.48 log10 CFU/g)
compared with 5 min (5.65 log10 CFU/g) and 10 min
exposure (5.64 log10 CFU/g). In the mice infected with
P. aeruginosa ATCC27853, intratracheal administration of
cysteamine reduced bacterial burden in the lungs from
8.17 ± 0.08 log10 CFU/g (control animals) to 7.86 ± 0.18
log10 CFU/g (cysteamine-treated animals).It is worth noting that these in vivo assays employed
only one or two doses of cysteamine, whereas it is most
likely that multiple doses (i.e. daily or twice daily dosing)
would be expected for the treatment of CF in a clinical
setting. It is therefore not unreasonable to assume at
least an equal, or even greater, reduction in respiratory
tract bacterial burden following repeat dosing with cyste-
amine, especially considering its sustained in vitro post-
antimicrobial effect. Furthermore, nebulisation may not
be the administration route via which cysteamine/Lyno-
vex® is delivered; dry powder inhalation and other modes
also being applicable and potentially providing greater
drug delivery efficiency.
Conclusions
As a first-in-class combination mucolytic-antibiofilm-
antimicrobial agent, cysteamine (as Lynovex®) has the
potential to offer a novel way forward in the treatment
of the chronic and recurrent respiratory infections of
cystic fibrosis. Previous clinical experience and our
own data point to cysteamine as being safe. Furthermore,
cysteamine should be applicable in all cystic fibrosis dis-
ease genotypes/phenotypes, not a mutation-specific treat-
ment in its recovery/improvement of respiratory health
and function.
Cysteamine could potentially break the cycle of progres-
sive lung damage and recurrent infections in cystic fibro-
sis. Cysteamine’s manifold actions of mucus and biofilm
disruption and antimicrobial impact on the bacteria these
structures support could achieve this end. As an adjunct
therapy with existing antibiotic treatment regimens, a
further advantage of cysteamine/Lynovex® is that its use
would not require significant modification to cystic fi-
brosis therapy schedules already in place. Instead, cyste-
amine/Lynovex® could potentiate and extend the effects
of the ‘older’ therapeutics that remain the core of existing
exacerbation interventions and longer term maintenance.
Lynovex® (cysteamine) is already designated as an or-
phan therapeutic candidate for the treatment of cystic
fibrosis and our intention is to move forward with devel-
opment of this compound in oral and inhaled form for the
control/eradication of the CF respiratory microbial burden.
This would apply both to exacerbations and also longer
term maintenance of pulmonary health in adult and paedi-
atric cystic fibrosis patients.
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